Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sartorius Stedim Biotech SA Expands Product Portfolio in Cell Culture Range via Cooperation with Lonza Group AG


Wednesday, 19 Dec 2012 05:16am EST 

Sartorius Stedim Biotech SA (SSB) announced an expansion of its product array in the cell culture range as it signed a cooperation agreement with Lonza Group AG on long-term, global collaboration in the field of cell culture media. The cooperation agreement provides that SSB will assume global sales and marketing of Lonza's media and buffers used in the manufacture of protein-based therapeutics and vaccines, while Lonza will continue to carry out development, manufacture and logistics operations for these products. New product development will be mutually performed. The cell culture media, which are usually sold in liquid or powder form to biopharmaceutical customers, are to be successively converted to packaged forms as ready-to-use, prefilled SSB sterile single-use bags. Furthermore, Lonza and SSB have agreed that these cell culture media will be sold under both brands in a co-branding arrangement. 

Company Quote

112.75
 --
21 Oct 2014